Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Internal Medicine
•
Pulmonology
Do you ever consider continuing annual LDCT chest for lung cancer screening in patients who quit smoking more than 15 years ago?
Unlike USPTF and CMS guidelines, NCCN and ACS do not have a criterion for <15 years since quit
Related Questions
Would you offer lung SBRT in a patient with Pulmonary Langerhans Cell Histiocytosis (PLCH)?
What is your approach to radiographically suspicious lung nodules for which initial biopsy was negative for malignancy?
Do you use any drugs prophylactically to reduce the risk of radiation pneumonitis in lung SBRT?
Do you perform EBUS-TBNA for staging in patients with biopsy proven malignant lung nodules with no lymphadenopathy on CT chest and PET scan?
How do you decide between neoadjuvant or perioperative chemoimmunotherapy, as per Checkmate 816 or KEYNOTE-671, for early-stage NSCLC?
Would a metal endobronchial stent within the treatment field change your radiation treatment plan for a thoracic malignancy?
How small of a nodule would you attempt to biopsy with robotic bronchoscopy?
At what age do you stop LDCT chest for lung cancer screening?
Do you perform routine interval lung cancer screening in non-smokers who are 1st degree relatives of patients with non-smoking related lung cancers with known EGFR mutations?
Is there increased risk with lung SBRT in a patient who has a mild asymptomatic pneumothorax in the field after CT-guided needle biopsy?